ALBERT

Description: Objective: To evaluate the efficacy and safety of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in patients with acquired severe aplastic anemia (SAA), who lacked suitable related or unrelated HLA-matched donors. Methods: 39 SAA patients underwent haplo-HSCT from Jul 2012 to Jun 2015 at our center. There were 23 males and 16 females at a median follow-up of 11 (range, from 0 to 36) months. The median time from diagnosis to transplantation was 1 (range, from 0.5 to 52) months. The median ages of SAA patients and related haploidentical donor were 23 years (range, 9 to 51years) and 45 (range, from 21 to 61) years, respectively. All patients were given BuCy plus ATG conditioning regimen. GVHD prophylaxis regimen consisted of cyclosporine A (CsA), mycophenolate motetil (MMF), and short-term methotrexate. Results: Stem cells were collected from bone marrow in 23.08% (n=9) of patients, peripheral blood in 2.56% (n=1), bone marrow plus peripheral blood in 74.36% (n=29) patients. 36 patients received haplo-HSCT combined with the third part of cord blood transfusion 92.31%. The median stem cell dose transplanted was 9.76 (range, from 4.02 to 20.10)×108/kg for mononuclear cells, while 3.4 (range, from 1.05 to 8.60)×108/kg for CD34 cells. 36 patients achieved neutrophil engraftment at a median of 12 (range, from 9 to 28) , and 29 patients achieved platelet engraftment at a median of 29 (range, from 10 to 26) days. Cumulative incidence of III°~IV° acute graft versus host disease (aGVHD) was 8.9±4.9%. 6 patients died of transplant-related mortality (TRM), including 4 from severe infection, and 1 from TMA. The overal survival rate of all patients was 83.2%±6.4% Conclusions: Haplo-HSCT is likely to be an option for SAA patients without suitable related or unrelated HLA-matched donors, in consideration of the acceptable TRM and severe GVHD incidences. Disclosures No relevant conflicts of interest to declare.

Description: Purpose We present the result of a comparison study between conventional chemotherapy and HCT for Peripheral T-cell lymphomas (PTCLs) in our center, especially the comparison between allo-HCT and auto-HCT. Patients and Methods From July 2007 to July 2014, 112 cases were analyzed retrospectively. All 112 patients were high risk group (IPI®3-4), 52 patients received conventional chemotherapy alone and 60 patients underwent HCT. In HCT group, Twenty-one (36.5%) patients received allo-HCT and thirty-nine patients (63.5%) received auto-HCT. Before receiving transplantation, 40 patients were in complete remission (CR), 2 patients were in partial remission (PR) and 18 patients were in refractory or relapse (NR). In the 18 NR patients, 11 patients accepted allo-HCT and 7 patients accepted auto-HCT. Patients¡¯ baseline characteristics were listed in Table 1 and Table 2. Results In this study, the longest follow-up time was 76 months and the shortest follow-up time was only two months. After chemotherapy, 31/52 patients achieved complete remission (CR)£¬5/52 patients achieved PR and 16/52 patients were not remission£¡§NR). The overall response rate was 69.2%. However, 14 patients suffered relapse in 36 responding patients, the recurrence rate was close to 50%. In allo-HCT group, 19/21 patients achieved CR and 2/21 patients died of severe infection within 100 days after HCT. In auto-HCT patients, 35/39 patients achieved CR and 4/39 patients were in NR. 7 patients experienced relapse after auto-HCT. After a median follow-up of 33.5 months, the K-M analysis showed that the 5-year PFS for HCT and chemotherapy were 60% and 30% (p =0.006), the 5-year OS were 65% and 33% (p =0.007). The difference between the two groups was significant The 5-year PFS for auto-HCT and allo-HCT were 61% and 60% (p=0.724). The 5-year OS were 62% and 61% (p=0.724). In transplant group, the 5-year OS for patients who were CR or NR before transplantation were 81% and 53% (p=0.303). The one-year cumulative TRM of allo-HCT and auto-HCT were 22.5% and 7.8% (p=0.250). For patients whose ages are below 50, the 2-year PFS for HCT and chemotherapy were 62.7% and 34.8% (p=0.017), the 3-year OS were 71.2% and 36.7% (p=0.033). The one-year TRM of HCT and chemotherapy were 15.5% and 12.4% (p=0.203). For patients more than 50 years old, the 1-year OS for HCT and chemotherapy were 85.7% and 66.5% (p=0.384). And the one-year TRM of HCT and chemotherapy were 28.6% and 33.3% (p=0.352). Conclusion The majorities of PTCL patients are at high risk and have a high recurrence rate after conventional chemotherapy alone. Our results suggest that HCT is superior to conventional chemotherapy in long-term survival for PTCLs and HCT is feasible for high-risk patients with low TRM, especially in the young patients. Therefore, HCT should be considered to be the first-line therapy in high risk PTCL patients. As to PFS and OS, there seems to be no difference between auto-HCT and allo-HCT. While before transplantation, there are more NR and relapsed patients in allo-HCT group, we recommend allo-HCT for refractory and relapsed patients. Table 1. Patient characteristics Parameters Chemotherapy HCT p value Number 52 60 Gender(female/male) 16/36 16/44 0.521 Median Age 45 29 0.003 Histological subtypes N PTCL-NOS 9 17 ALK-negative ALCL 15 15 AITL 15 17 NK/T 13 11 High risk factors B-symptoms 27 25 0.436 IPI score ®3 52 60 1.000 Ann Arbor III-IV stage 40 40 0.376 Evaluated LDH 40 42 0.546 Response to chemotherapy N CR 31 40 PR 5 2 NR 16 18 Responses to transplantation N N CR 54 PR 0 NR 4 Uncertain 2 Table 2. Patient characteristics of transplantation group Parameters Auto-HCT Allo-HCT Number 39 21 Histological subtypes PTCL-NOS 12 4 ALK-negative ALCL 13 4 AITL 7 9 NK/T 7 4 Conditioning regimen BEAM 39 0 BUCY 0 11 TBI+BUCY 0 10 Donor source N Matched unrelated donor 8 Matched sibling donor 4 Haploid donor 8 Cord blood 1 Disease status before HCT CR 30 10 PR 2 0 NR 7 11 Disease status after HCT CR 35 19 PR 0 0 NR 4 0 uncertain 0 2 Disclosures No relevant conflicts of interest to declare.

Description: Purpose: Allogeneic stem cell transplantation (alloSCT) has significantly improved the prognosis of patients with Int/High risk myelodysplastic syndrome (MDS). However, it is associated with severe graft-versus-host disease (GVHD), and the lack of available human leukocyte antigen (HLA)-matched donors remains a major obstacle.In the present study, we explored the clinical value and feasibility of HLA-mismatched or HLA-matched hematopoietic stem cell infusion combined with chemotherapy (micro-transplantation) as a new therapy to improve the prognosis of MDS patients. Methods: 6 patients diagnosed with Int/High myelodysplastic syndrome between May 15 2014 and May 5 2015 who received micro-transplantation were enrolled in our study. Their diagnoses were defined by the FAB and WHO criteria, including 1 patient with RARS, 2 with RCMD, 1 with RAEB-1, 1 with RAEB-2 and 1 with CMML. Among them, one patient with RCMD was diagnosed as secondary MDS who received radiotherapy with lung cancer. According to IPSS, 2 patients with Int-1 risk group, 1 patients with In-2, and 3 patients with high risk group. 4/6 presented with complex karyotype, 3/6 with P53 mutation and 1/6 with mutation of ASXL1 and DNMT3. Before receiving micro-transplantation, the treatment of 4 patients were unsuccessful: one patient with RARS who received supportive therapy and vitamin B6 for 18 month was still dependent on RBC transfusion, with hemoglobin between 39g/l and 50g/l, and his iron overloading was severe; one patients with RCMD who received decitabine therapy and acquired hematopoietic improvement; one patient with CMML received induction chemotherapy of CAG and did not present with PR or hematologic improvement; one patient with RAEB-2 achieved CR after the first cycle of decitabine therapy (20mg/m2*5d) and relapsed after the next three courses. Before the micro-transplantion, remission induction chemotherapy consisted of intra- venous infusion of decitabine (25mg/m2) for 4 days (-9,-8,-7,-6), cytarabine (235mg/m2) for 3 days (-5, -4, -3). For one patients with RAEB-2, we increased the dose of cytarabine to 1g/m2, q12h for 3 days (-5, -4, -3). Among the 3 patients with high risk IPSS scores, 2 patients who presented with P53 mutation additionally received another Idarubicin (10mg) or VP-16 (100mg). Results: The median number of donor peripheral blood mononuclear cells was 4.26*10E8/kg (range:2.55-6.18), and the median number of CD34+ cells was 1.275*10E8/kg (range:0.85-1.6). The median time of patients with NE ≥0.5×109/L was 13 ( range:10-18) days, and median time of Plt≥20×109/L was 13 ( range:11-16) days. After miro-transplantation, bone marrow test indicated that all the six patients received CR, and their karyotype and molecular mutation became negative. Peripheral blood routine test suggested the significant hematopoietic improvement, and the STR was between 1.3% and 7.8%. No patients presented with acute GVHD, and all the six patients were alive until now, with median follow-up time after micro-transplantation was 6 months (2-14month). Conclusion: In present study, micro-transplantation therapy achieved a promising outcome in patients with Int /High risk MDS, all patients achieved hematopoietic improvement and no patients died for severe infection or GVHD. For MDS patients, those with older age, without HLA-matched donor, or with poor performance status who can not tolerated the blative or reduced intensity conditioning, micro-transplantation may be a new choice. Considering the small number of patients and different conditioning therapy we used before micro-transplantation in our study, further study may been needed to verify our findings. Disclosures No relevant conflicts of interest to declare.

Description: Abstract 4602 Backgrouds: NK/T cell lymphoma is a rare disease, but usually shows a highly aggressive clinical course and its prognosis is poor due to the stumbling block in early diagnosis and effective management. Until present, there are no consensus treatments especially for recurrent patients. Bortezomib, and other new drugs are subject to active investigation, although only limited preliminary information is available. Here, 3 cases of refractory disseminated NK/T cell lymphoma were treated with Bortezomib plus high dose chemotherapy as salvage therapy. Patients and methods: From 2008–2010, 3 cases of refractory NK/T cell lymphoma, 2 males, 1 female, aged from 26–35, PS 0–1 were enrolled. Former treatments included at least 2–9 months of chemotherapy (CHOP or CHOP like) and local radiotherapy. The stage of patients was III in 2, IV in 1. IPI scores were all in high risk. Result: 3 patients received high dose chemotherapy combined with bortezomib as re-induction treatment. 2 patients received hyperCVAD as induction therapy with bortezomib given 1.3mg/m2 on d2, 5, 9 and 12. 1 patient received bortezomib and SMILE protocol, included bortezomib 1.3 mg/m2 on days1, 4, 8, 11, dexamethasone 20 mg twice a day on days 1 through 4, etoposide 100 mg/m2 on days 1 through 3, ifosphamide 1.0 g/m2 on days 1 through 5, methotrexate 30 mg/m2 on days 4, 11, L-asparaginase 6000U/m2 on days 7, 9, 11, 13, 15. All 3 patients had response to the treatment. HyperCVAD, HDAC+MTX and SMILE protocol combined with bortezomib were also given to the patients as consolidation therapy for 1–4 courses. After 2 course of treatment, 1 patient got CR, 2 got PR. Then ASCT was performed. Condition protocol was SEAM+Bz1.3 mg/m2 on days-4, -1. At a median follow-up for 15 months, the median duration of PFS was 12 months. No PN was found in all patients. SAE were neutropenia and thrombocytopenia grade 4, mucositis grade 3, increase AST grade 2 in 3 patients and HZV infection in 1. Conclusion: Bortezomib combined with high dose therapy may be effective salvage therapy in some refractory disseminated NK/T cell lymphoma, especially in young adults. More cases need to be carefully investigated to explore the effect and side effect in bortezomib plus high dose therapy in this special disease. Disclosures: No relevant conflicts of interest to declare.

Description: Introduction The Sequential priming regimen has been used for newly diagnosed and relapsed/refractory patients with acute myeloid leukemia unfit for intensive chemotherapy. Unfortunately, the rate of CR is not hopeful. Hypomethylating agent, decitabine is active in eldly patients with AML. Long-term decitabine combined with sequential priming regimen treats these patients, its efficacy and side effects and optimal dose are unknown. Methods A total of 14 inpatients with AML during the period from February 2013 through May 2014 were enrolled in this study, including 8 men and 6 women. The subjects had a median age of 56 years (range, 25–71 years), with 10 cases at ages of over 50 years. Of all participants, transformation of myelodysplastic syndromes (MDS) into AML occurred in 6 cases; 8 cases received treatment for the first time, 5 cases had refractory AML, and 1 case had relapsed AML. Normal chromosome was detected in 9 cases, and chromosomal abnormality +8, t(1;9), -y,t(8;21), t(8;21),mar and complex chromosomal abnormality occurred in one case each; 6 cases (42.9%) had gene mutations, including NPM1/DNMT3, CEBPA, FLT3-ITD/NPM1/DNMT3, FLT3-ITD/NPM1, DEK/CAN and U2AF1, of one case for each mutation. There were 12 cases with concomitant diseases. There were 5 cases with an Eastern Cooperative Oncology Group (ECOG) score of 4 and 7 cases with an ECOG score of 3. The chemotherapy regimen was decitabine at a dose of 20 mg/m2 on days 1 to 6 or 8, and the IAG priming regimen was used in 5 cases, CAG regimen in 5 cases, and HAG regimen in one case. There were 5 cases undergoing a half cycle of the induction therapy (7 days) and 9 cases undergoing a whole cycle of the induction therapy (14 days). A cycle of therapy achieved complete response in 12 cases (85.7%) and no response in 2 cases, including one recurrent case with FLT3-ITD mutation following autologous stem cell transplantation and a refractory case with DEK/CAN mutation. Results A half cycle ofinduction therapy resulted in completed remission in 4 out of 5 cases, and the whole cycle of therapy resulted in 8 out of 9 cases. All 8 cases receiving therapy for the first time achieved complete remission, and 3 out of 5 refractory cases achieved complete remission. The median time for nonerythroid cell (NEC) count of 〈 0.5 × 105/L and platelet blood cell (PBC) count of 〈 20 × 109/L was 12 (range, 0–37) and 18 (range, 0–37) days, respectively. During the half cycle of induction therapy, the median time for NEC count of 〈 0.5 × 105/L and platelet blood cell (PBC) count of 〈 20 × 109/L was 17 (range, 6–37) and 18 (range, 7–38) days, respectively, whereas being 11 (range, 0–30) and 12 (range, 0–28) days during the whole cycle of induction therapy, respectively. There were 6 cases with side effects, including 4 cases achieving complete remission. Post-chemotherapy complications included infections, bleeding, and liver function impairment. Of the 10 cases complicated with infections at the first diagnosis, 2 cases developed aggravated pulmonary infection and 4 cases developed new infections at the stage of bone marrow suppression, including one case with infection at the perianal region, one case with infection at pharynx, one case with influenza A, and one case with skin infection. No therapy-induced death was observed. Conclusions Long-term decitabine treatment in combination with sequential priming regimen is effective for the AML patients undergoing treatment for the first time and recurrent and refractory AML, which is comparable to the standard "7 + 3" remission-induction therapy. In addition, it may improve the prognosis of AML patients with chromosomal abnormality and gene mutations, particularly for patients with DNMT3 and FLT3-ITD mutations. Further multi-center, prospective clinical trials are required to evaluate the efficacy of the new regimen for AML and optimize the treatment regimen. Disclosures No relevant conflicts of interest to declare.

Description: Background: CAR-T immunotherapy has shown remarkable promising results for relapsed/ refractory (R/R) acute lymphoblastic leukemia (ALL). However, CD19-targeted CAR T cell therapy for R/R ALL has a relapse rate of approximately 50% at 1 year after CART therapy, and the most common mechanism of relapse is due to CD19 antigen loss or decreased target expression on the surfaces of the lymphoblastic leukemia cells. Potential approaches to overcome this challenge include engineering CAR T cells to achieve multispecificity and to respond to lower expression levels of target antigens by dual target CAR T strategies. Objective: In order to evaluate the efficacy and safety of CD19/CD22 dual target CAR T cells for R/R ALL patients to determine if targeting multiple antigens can prevent treatment failure and improve response rates and durability of response. Method: A novel CAR T cells with tandem targeting CD19 and CD22 antigens and a third generation CAR construct of CD28 and OX40 co-stimulatory domains were administered to 23 patients with R/R ALL with a median age of 24(6-56)years. High-risk patients were enrolled in this cohort, including 10 with BCR-ABL+ALL (6 of 10 with T 315I mutation), 4 with TP53 mutation, 2 with Ph-like ALL and 3 with relapsed ALL post allo-HSCT. The patients received a single infusion of CAR T cells with dose escalation schedule:10%--30%--60%. The median infusion dose of CAR T cells was 1 (0.5- 2.5) ×107cells/kg. Results: The median follow-up was 9 (3.5-20) months. The day 28 CR/CRi rate was 100% with21/22 (95.5%) molecular remission. Six-month OS was 94.4% and RFS was 76.9%. One-year OS was 57.2% and RFS was 67.3%. One-year OS of high tumor burden (BM blast〉 30%)(15/22) and low tumor burden(BM blast≤30%)(7/22) was 47.5% and 75% respectively (p〉0.05). The 1-year OS of the CAR T- to- allo-HSCT group(14/22) was better than that of the non-transplant group(8/22) (OS 72.9% vs. 26.7%, p = 0.116). The cumulative relapse rate of 6 months and 1 year were 23.1% and 32.7% respectively. The overall incidence of CRS were 91% included 22.7%grade III CRS ,4.5% grade IV CRS and 0% severe CRES. Only one patient presented MAH syndrome and was cured with low dose dexamethasone. There was no CAR T-related death. Conclusions: The tandem CD19/CD22 dual target CAR T cells therapy is a safe and high efficacy treatment for R/R ALL patients. It is possible that multi-targeted CAR-T cell therapy may overcome this resistance mechanism and improve clinical outcomes. Disclosures No relevant conflicts of interest to declare.

Description: Introduction The prognosis was poor and the rate of refractory and relapsed was high for FLT3-mutated AML. The remission durations are shorter. Once relapsed, the disease is rapidly fatal. Some patients were often refractory to induction. While there was some success with immediate allogenic transplantation, it was shown that patients without FLT3 mutations were still prone to high rates of relapsed, posing a tremendous clinical challenge. At the moment there are no clear guidelines for treating these special patients in both the preliminary and induction phase. Method Six of refractory and relapsed AML with FLT3-ITD mutation were evaluated, with a medium age of 43 (33-61 years old) and a male/female ratio of 3/3. Four of the cases were refractory (1 case at M2, 1 case at M4, and 2 cases at M5), while 2 were relapsed (1 case at M1, 1 case at M5). Two cases had FLT3-ITD mutation only, one patient had FLT3-TKD mutation only, 2 cases was coexisted NPM1 mutation, and one patient was combined DNMT3A mutation. Two cases were treated with sorafenib 200 mg bid or 400 mg bid, five days per week, while four cases were treated with sorafenib (same dosage) with combined half-course IAG or AAG chemotherapy (7 days) during induction. Results Four cases with combined therapies resulted in CR, while the symptoms in 2 relapsed patients with sorafenib-only treatment were unable to be alleviated. After the treatment was terminated, these two patients expired as the disease progressed for 6 months. The time range of sorafenib use was between 9 - 260 days, with a medium of 34 days. The 4 cases of CR included 2 cases with only FLT3-ITD mutation, 1 case with only FLT3-TKD mutation, and 1 case of combined NPM1 mutation. Three of the four cases received hematopoietic stem cell transplantation after the symptoms were reduced. The survival periods were 62, 90, and 117 days respectively. The last case exhibited a recurrence after consolidation chemotherapy was applied in place of sorafenib. FLT3-ITD was negative during the relapsed, and the symptoms were controlled after cladribine treatment with large doses of cytarabine. The major toxicities observed during the induction phase were neutropenia, thrombocytopenia and infections. All patients experienced grade IV WHO neutropenia and thrombocytopenia. The medium days of agranulocytosis was 18 days (4 - 27 days), platelets

Description: Background :Relapse remains a major cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially in patients with high-risk acute myeloid leukemia (AML). Therefore, how to eradicate the minimal residual disease and prevent of relapse are of great importance to improve the outcome of allo-HSCT for these high risk AML patients. M ethods :We retrospectively investigated decitabine (DAC) as part of a modified Bu-Cy regimen for high-risk AML patientsundergoing allo-HSCT. Fifty-nine patients received DAC (20 mg/m2/d,i.v.) for 5 days, followed by modified Bu-Cy (DAC group). A control (CON) of 177 patients (pair-matched 1:3) received modified Bu-Cy only. Results:Median follow-up was 402 (85-1504) days. There was no difference in graft versus-host disease occurrence. Treatment-related mortality (day 100) was 0% (DAC) and 6.2% (CON). The DAC group had better 2-year overall survival (OS, 77% versus 64%, P=0.018) and leukemia-free survival (LFS, 73% versus 56%, P=0.007). The differences were more substantial among patients with active disease: OS, 83% (DAC) versus 47% (CON), P=0.01 and LFS, 77% (DAC) versus 34% (CON), P=0.002. Median time to relapse was 187 days (DAC) versus 86 days (CON) and two-year relapse rates were 10% (DAC) and 49% (CON) for patients with active disease. Patients with cytogenetic monosomy 7 or 7q- abnormality responded better. Conclusions: Our data indicate that novel conditioning regimen containing DAC may be an effective and well-tolerated strategy and confer a subgroup-specific survival advantage in high-risk AML patients undergoing allo-HSCT. Disclosures No relevant conflicts of interest to declare.

Description: Objectives Clinically, primary gastric diffuse large B cell lymphoma (PG-DLBCL) is not encountered commonly. The optimal treatment of PG-DLBCL remains controversial. Whether patients should receive surgical resection, Rituximab or not was most concerned about. Here we analized 83 patients with PG-DLBCL retrospectivly and evaluated the effect of surgical option and Rituximab in the treatment of PG-DLBCL. Methods From January 2009 to December 2014, 83 cases of PG-DLBCL patients in the First Affiliated Hospital of Soochow University were retrospectively studied. Forty cases received surgical resection plus chemotherapy (group A) and 43 patients underwent chemotherapy alone (group B). The operation mode is decided by the surgeon according to the patients¡¯ current condition and the chemotherapy regimens of two groups were CHOP or R-CHOP. Patients¡¯ characteristics were listed in Table 1. The main outcomes of overall survival (OS) and the progression free survival (PFS) were analized by using the Kaplan-Meier (K-M) method. Results The K-M analysis showed that the 3-year PFS and OS in group A were 66.7% and 68.4%, respectively. On the other hand, the 3-year PFS and OS of group B were 82.6%and 85.7%, respectively. There is no significant difference between the two groups. For patients received CHOP or R-CHOP, the 5-year OS were 77.7% and 78.2% (p=0.178). And the 3-year PFS were 74.9% and 75.5% (p=0.347). The difference between the two groups was not statistically significant. In group A, the 5-year PFS of R-CHOP group and CHOP group is 62.5% and 71.2% £¨p=0.747£©, the 5-year OS of R-CHOP group and CHOP group is 64.2% and 73.6% (p=0.853). In group B, the 5-year PFS of R-CHOP group and CHOP group is 83.4% and 81.8% £¨p=0.706£©, the 5-year OS of R-CHOP group and CHOP group is 85.7% and 83.5% (p=0.753). The univariate analyses indicated that age and lactate dehydrogenase (LDH) level were related to prognosis. Multivariate analysis of prognostic factors with a Cox model showed that IPI was the only independent prognostic factor. Conclusions This study shows that PG-DLBCL patients have a similar long-term survival rate when adopted surgery plus chemotherapy. Therefore, resection of the primary tumor before systemic chemotherapy does not improve the survival of the patients with PG-DLBCL. At the same time, the addition of Rituximab to chemotherapy doesn¡¯t make difference for the survival of PG-DLBCL. More prospective clinical trials about the effect of surgical operation and rituximab are needed to confirm the results of our study. Table 1. Patients¡¯ baseline characteristics Patients £¨%£© P value With surgical resection(Group A, n£½40£© Without chemotherapy (Group B, n £½ 43 £© Gender Male 19£¨47.5%£© 24£¨55.8%£© 0.449 Female 21£¨52.5%£© 19£¨44.2%£© Age ¡Ü60 15£¨37.5%£© 22£¨51.2%£© 0.211 £¾60 25£¨62.5%£© 21£¨48.8%£© Ann Arbor Stage I/II 13£¨32.5%£© 7£¨16.3%£© 0.084 Stage III/IV 27£¨67.5%£© 36£¨83.7%£© ECOG £¼2 19£¨47.5%£© 22£¨51.2%£© 0.739 ¡Ý2 21£¨52.5%£© 21£¨48.8%£© Treatment plan R-CHOP 23£¨57.5%£© 24£¨55.8%£© 0.887 CHOP 17£¨42.5%£© 19£¨44.2%£© LDH ¡Ü245 24£¨60.0%£© 27£¨62.8%£© 0.794 £¾245 16£¨40.0%£© 16£¨37.2%£© IPI ¡Ü2 13£¨32.5%£© 15£¨34.9%£© 0.818 £¾2 27£¨67.5%£© 28£¨65.1%£© ECOG: Eastern Cooperative Oncology Group; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; LDH: lactate dehydrogenase Disclosures No relevant conflicts of interest to declare.